CT identifier | Drug | Method of action | Cancer | Approved/phase study |
---|---|---|---|---|
Targeting T lymphocytes | ||||
NCT01844505 | Nivolumab | Anti-PD1 | mMM | Phase 3 |
NCT01642004 | Nivolumab | Anti-PD1 | NSCLC | Phase 3 |
NCT01354431 | Nivolumab | Anti-PD1 | mRCC | Phase 2 |
NCT00094653 | Ipilimumab | Anti-CTLA4 | mMM | Approved |
NCT00861614 | Ipilimumab | Anti-CTLA4 | PC | Phase 3 |
NCT01450761 | Ipilimumab | Anti-CTLA4 | SCLC | Phase 3 |
NCT01285609 | Ipilimumab | Anti-CTLA4 | NSCLC | Phase 3 |
NCT01693783 | Ipilimumab | Anti-CTLA4 | Cervical cancer | Phase 2 |
NCT01860430 | Ipilimumab | Anti-CTLA4 | HNSCC | Phase 1B |
NCT00257205 | CP-675,206 | Anti-CTLA4 | mMM | Phase 3 |
Blocking immune cell recruitment | ||||
NCT01346358 | IMC-CS4 | CSFR1 antagonist | Advanced tumours | Phase 1 |
NCT01316822 | ARRY-382 | CSFR1 antagonist | Advanced tumours | Phase 1 |
NCT01015560 | MLN1202 | Anti-CCR2 | Bone metastases | Phase 1 |
NCT01032122 | Rituximab | Anti-CD20 | mMM | Phase 1 |
NCT01376713 | Ofatumumab | Anti-CD20 | mMM | Phase 2 |
NCT01456585 | CP-870,893 | Anti-CD40 | mPC | Phase 2 |
NCT01103635 | CP-870,893 | Anti-CD40 | mMM | Phase 1 |
NCT00607048 | CP-870,893 | Anti-CD40 | Solid tumours | Phase 1 |
Reprogramming immune cells | ||||
NCT00169104 | G-CSF | Sustained neutrophilia | mBC | Phase 1/2 |
NCT00014456 | G-CSF | Â | Solid tumours | Phase 1 |
NCT00070629 | Promune | TLR9 agonist | NSCLC | Phase 2 |
NCT00043394 | Promune | TLR9 agonist | BC | Phase 2 |
NCT00070642 | Promune | TLR9 agonist | MM | Phase 2 |
NCT00043407 | Promune | TLR9 agonist | RCC | Phase 1/2 |
NCT00292045 | Promune | TLR9 agonist | PC | Phase 1 |
NCT00669292 | Promune | TLR9 agonist | Esophageal cancer | Phase 1/2 |
Multiple | Vaccines (Multiple targets) | T-cell activation | Multiple cancers | Â |
TH2-- > TH1 reprogramming | ||||
NCT01642290 | Anti-OX40 | Anti-OX40 | mBC | Phase 1/2 |
NCT01644968 | Anti-OX40 | Anti-OX40 | Advanced cancer | Phase 1 |
NCT01689870 | Anti-OX40 | Anti-OX40 | mMM | Phase 1/2 |